Search

China pioneers biosecurity report against ASF

Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.

Mareks Disease Poultry Chicken

Five things you need to know to keep poultry free from outcomes of one of the most common virus affecting the animals’ immune systems.

Development Biotechnology sustainable cell culture

Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint

Boehringer Ingelheim announces appointments Board of Managing Directors

Knowing the enemy: PRRS and PCVD

The swine industry is constantly vigilant of viruses such as PRRS and PCV2 (PCVD). Learn about prevention, symptoms knowledge, and control measures to make a difference.

Smart Factory: Digitalizing production facilities

How our digitalized production facilities help our colleagues and patients

Boehringer receives SBTi validation for CO2 reduction targets

Boehringer Ingelheim receives SBTi validation for CO2 reduction targets

Biopharmaceuticals: large molecules, enormous potential

Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.

Second cancer immunotherapy partnership with 3T Bio

India: Many positive developments for the population

A conversation with interim country manager Sandip Agrawal about a young and growing country

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor

Tomorrow's leaders

We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.

Boehringer founding sponsor of CKM Health Initiative

Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative

European_Commission_approves_nintedanibSSc-ILD

Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease

Results for Jardiance EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack

Full data chronic kidney disease trial efficacy

Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease

Tackling supply chain challenges for a country at war

We are there for our patients – even in crisis regions. A supply chain success story with our Ukrainian colleague Tetiana Nagirna from Kyiv.

Global Top Employer 2023

Survodutide Phase III study weight loss

Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity

Employees empower small dairy producers

Boehringer Ingelheim social intrapreneurship helps farmers improve animal welfare and the well-being of rural communities in Southern India.

Career tips from our Global Head of HR

Sven Sommerlatte explains how important it is to reflect on the personal career strategy.

Resizing our Carbon Footprint

The ecological balance of the world is at a tipping point.

FDA accepts new chronic kidney disease treatment application

Are combination therapies the answer to battling KRAS cancers?

Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal

On two wheels for more animal health

Cowtribe’s social entrepreneurs win Boehringer Ingelheim's Accelerator Program.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers